Literature DB >> 11170955

Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy.

F Saulsbury1.   

Abstract

Opportunistic infections are a major source of morbidity and mortality in children and adults infected with human immunodeficiency virus (HIV). In addition, organ-specific complications of HIV infection, such as cardiomyopathy, nephropathy, encephalopathy, and others, contribute substantially to the morbidity and mortality associated with HIV infection. Highly active antiretroviral therapy (HAART) has produced a dramatic decline in the incidence of opportunistic infections among patients with HIV infection. Nevertheless, there is very little information concerning the value of HAART for organ-specific complications of HIV infection. In this report, we describe 3 children with HIV infection in whom the dominant clinical manifestations were cardiomyopathy, red cell aplasia, and nephropathy. HAART produced a decrease in the HIV ribonucleic acid level, an increase in the CD4 cell count, and resolution of the organ-specific complications in all patients. These cases add to our knowledge concerning the benefits of HAART for children with HIV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170955     DOI: 10.1086/318493

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  2 in total

1.  Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors.

Authors:  Warren A Andiman; Miriam C Chernoff; Charles Mitchell; Murli Purswani; James Oleske; Paige L Williams; Hans Spiegel; Phil Gona; George R Seage
Journal:  Pediatr Infect Dis J       Date:  2009-07       Impact factor: 2.129

Review 2.  Pharmacotherapeutic options for kidney disease in HIV positive patients.

Authors:  Anam Tariq; Hannah Kim; Hashim Abbas; Gregory M Lucas; Mohamed G Atta
Journal:  Expert Opin Pharmacother       Date:  2020-09-21       Impact factor: 4.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.